David A. Hyman, MD, JD, on Inclusive Shared Savings

First International Summit on Interventional Pharmacoeconomics

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

Welcome and Introduction to Vi3C

Cost of Care

The ASCO Post Staff

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Cost of Care

Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Aug

Today In Oncology

David A. Hyman, MD, JD, on Inclusive Shared Savings

Related Videos

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Welcome and Introduction to Vi3C

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Kinase Inhibitor Approved for Nonsquamous NSCLC With HER2 TKD–Activating Mutations

Potential New Second-Line Standard of Care Emerges in Small Cell Lung Cancer

Mortality in Advanced-Stage Ovarian Cancer—Effect of Neoadjuvant Chemotherapy and Cytoreductive Surgery Case Volume

Smoking Cessation in Cancer Care: Challenges and Opportunities

GLP-1 Receptor Agonists vs Other Glucose-Lowering Drugs: Survival in Older Patients With Cancer and Diabetes